Breaking News, Financial News

Financial Report: Biogen Idec 1Q08

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 1Q Revenues: $942 million (+32%) 1Q Earnings: $163 million  (+23%) Comments: Growth in the quarter was driven by Avonex sales (+19% to $536 million), Tysabri sales (+283% to $115 million) and Rituxan revenues from the joint business arrangement with Genentech (+19% to $247 million). In the quarter, the company announced new Tysabri safety data showing a favorable benefit-risk profile and no cases of progressive multifocal leukoencephalopathy (PML) since its re-launch in t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters